Literature DB >> 12122102

Development of an improved vaccine for anthrax.

Stephen H Leppla1, John B Robbins, Rachel Schneerson, Joseph Shiloach.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12122102      PMCID： PMC151073          DOI： 10.1172/JCI16204

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  29 in total

1.  Large-scale production of protective antigen of Bacillus anthracis in anaerobic cultures.

Authors:  M PUZISS; L C MANNING; J W LYNCH; I ABELOW; G G WRIGHT
Journal:  Appl Microbiol       Date:  1963-07

2.  Studies on immunity in anthrax. V. Immunizing activity of alum-precipitated protective antigen.

Authors:  G G WRIGHT; T W GREEN; R G KANODE
Journal:  J Immunol       Date:  1954-12       Impact factor: 5.422

3.  Biological products; bacterial vaccines and toxoids; implementation of efficacy review. Final rule and final order.

Authors: 
Journal:  Fed Regist       Date:  2004-01-05

Review 4.  A toxoid vaccine for pertussis as well as diphtheria? Lessons to be relearned.

Authors:  R Schneerson; J B Robbins; J Taranger; T Lagergård; B Trollfors
Journal:  Lancet       Date:  1996-11-09       Impact factor: 79.321

5.  Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein.

Authors:  B M Price; A L Liner; S Park; S H Leppla; A Mateczun; D R Galloway
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

6.  Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity.

Authors:  P C Turnbull; M G Broster; J A Carman; R J Manchee; J Melling
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

7.  Virulence and immunogenicity in experimental animals of Bacillus anthracis strains harbouring or lacking 110 MDa and 60 MDa plasmids.

Authors:  I Uchida; K Hashimoto; N Terakado
Journal:  J Gen Microbiol       Date:  1986-02

8.  Anthrax spores make an essential contribution to vaccine efficacy.

Authors:  Fabien Brossier; Martine Levy; Michèle Mock
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

9.  Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies.

Authors:  Stephen F Little; Jeanne M Novak; John R Lowe; Stephen H Leppla; Yogendra Singh; Kurt R Klimpel; Burton C Lidgerding; Arthur M Friedlander
Journal:  Microbiology (Reading)       Date:  1996-03       Impact factor: 2.777

10.  Non-toxigenic derivatives of the Ames strain of Bacillus anthracis are fully virulent for mice: role of plasmid pX02 and chromosome in strain-dependent virulence.

Authors:  S L Welkos; N J Vietri; P H Gibbs
Journal:  Microb Pathog       Date:  1993-05       Impact factor: 3.738
View more
  53 in total

1.  Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo.

Authors:  Miroslav S Sarac; Juan R Peinado; Stephen H Leppla; Iris Lindberg
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

2.  Phase 1 study of a recombinant mutant protective antigen of Bacillus anthracis.

Authors:  Joseph A Bellanti; Feng-Ying C Lin; Chiayung Chu; Joseph Shiloach; Stephen H Leppla; German A Benavides; Arthur Karpas; Mahtab Moayeri; Chunyan Guo; John B Robbins; Rachel Schneerson
Journal:  Clin Vaccine Immunol       Date:  2011-12-21

3.  Identification of a protein subset of the anthrax spore immunome in humans immunized with the anthrax vaccine adsorbed preparation.

Authors:  Indira T Kudva; Robert W Griffin; Jeonifer M Garren; Stephen B Calderwood; Manohar John
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

4.  Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax.

Authors:  E D Williamson; I Hodgson; N J Walker; A W Topping; M G Duchars; J M Mott; J Estep; C Lebutt; H C Flick-Smith; H E Jones; H Li; C P Quinn
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

5.  Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity.

Authors:  Sherry R Crowe; Lori Garman; Renata J M Engler; A Darise Farris; Jimmy D Ballard; John B Harley; Judith A James
Journal:  Vaccine       Date:  2011-03-21       Impact factor: 3.641

6.  Genome engineering in Bacillus anthracis using Cre recombinase.

Authors:  Andrei P Pomerantsev; Ramakrishnan Sitaraman; Craig R Galloway; Violetta Kivovich; Stephen H Leppla
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

7.  The Gordon Wilson lecture: using genetic medicine to regenerate diseased organs and protect against the hostile environment.

Authors:  Timothy P O'Connor; Ronald G Crystal
Journal:  Trans Am Clin Climatol Assoc       Date:  2004

Review 8.  Genetic medicine strategies to protect against bioterrorism.

Authors:  Julie L Boyer; Ronald G Crystal
Journal:  Trans Am Clin Climatol Assoc       Date:  2006

9.  Imaging tumor endothelial marker 8 using an 18F-labeled peptide.

Authors:  Qimeng Quan; Min Yang; Haokao Gao; Lei Zhu; Xin Lin; Ning Guo; Guixiang Zhang; Henry S Eden; Gang Niu; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08-04       Impact factor: 9.236

10.  Domain specificity of the human antibody response to Bacillus anthracis protective antigen.

Authors:  Donald C Reason; Anuska Ullal; Justine Liberato; Jinying Sun; Wendy Keitel; Jianhui Zhou
Journal:  Vaccine       Date:  2008-06-02       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.